Cytokine production during myeloablative and reduced intensity therapy before allogeneic stem cell transplantation

Haematologica

Volumn 89, Issue 6, 2004, Pages 710-716

  Remberger, Mats ^a,b   Sundberg, Berit ^a  

^a Department of Clinical Immunology ^*  (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Cytokines; HSCT; Reduced intensity conditioning

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYTOKINE; FLUDARABINE; MYELOABLATIVE AGENT; THYMOCYTE ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOANALYSIS; BLOOD LEVEL; CHEMOLUMINESCENCE; CHILD; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DISEASE SEVERITY; DRUG MEGADOSE; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE;

ADOLESCENT; ADULT; AGED; ANTILYMPHOCYTE SERUM; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; CYTOKINES; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFANT; MIDDLE AGED; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 3042571520     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Goldman JM, Schmitz N, Niethammer D, Gratwohl A. Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe in 1998. Accreditation Sub-Committee of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 1998;21:1-7.
2. Ringdén O, Groth C, Aschan J, Bolme BP, Ljungman P, Lönnqvist B, et al. Bone marrow transplantation for metabolic disorders at Huddinge hospital. Transpl Proc 1990;22:198-202
3. O'Reilly RJ. Allogenic bone marrow transplantation: current status and future directions. Blood 1983;62:941-4.
4. Ringdén O, Labopin M, Gluckman E, Reiffers J, Vernant JP, Jouet JP, et al. Graft-versus-leukemia effect in allogeneic marrow transplant recipients with acute leukemia is maintained using cyclosporin A combined with methotrexate as prophylaxis. Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 1996;18:921-9.
5. Horowitz MM, Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb HJ, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990;75:555-62.
6. Krenger W, Ferrara JL. Dysregulation of cytokines during graft-versus-host disease. J Hematother 1996;5:3-14.
7. Ferrara JL, Cooke KR, Pan L, Krenger W. The immunopathophysiology of acute graft-versus-host-disease. Stem Cells 1996;14:473-89.
8. Antin J, Ferrara J. Cytokine dysregulation and acute graft-versus-host disease. Blood 1992;80:2964-8.
9. Teshima T, Ordemann R, Reddy P, Gagin S, Lin C, Cooke KR, et al. Acute graft-versus-host disease does not require alloantigen expression on host epithelium. Nat Med 2002;8:575-81.
10. Piguet PF, Grau GE, Allet B, Vassalli P. Tumor necrosis factor/cachectin is an effector of skin and gut lesions of the acute phase of graft-vs.-host disease. J Exp Med 1987;166:1280-9.
11. Remberger M, Ringdén O, Markling L. TNFα levels are increased during bone marrow transplantation conditioning in patients who develop acute GVHD. Bone Marrow Transplant 1995;15:99-104.
12. Holler E, Kolb H, Möller A, Kempeni J, Liesenfeld G, Pechumer H, et al. Increased serum levels of tumor necrosis factor alfa precede major complications of bone marrow transplantation. Blood 1990;75: 1011-6.
13. Ringdén O, Bäckman L, Sundberg B, Lönnqvist B, Tollemar J, Gahrton G, et al. Allogenic bone marrow transplantation for leukemia; factors of importance for long-term survival and relapse. Bone Marrow Transplant 1988;3:281-90.
14. Thomas E, Buckner C, Banaji M, Clift RA, Fefer A, Flournoy N, et al. One hundred patients with acute leukemia treated with chemotherapy total body irradiation and allogeneic marrow transplantation. Blood 1977;49:511-33.
15. Khouri IF, Keating M, Korbling M, Przepiorka D, Anderlini P, O'Brien S, et al. Transplant-lite: induction of graft-versus-malignancy using fludarabine- based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol 1998;16:2817-24.
16. McSweeney PA, Storb R. Mixed chimerism: preclinical studies and clinical applications. Biol Blood Marrow Transplant 1999;5:192-203.
17. Giralt S, Estey E, Albitar M, van Besien K, Rondon G, Anderlini P, et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood 1997;89:4531-6.
18. Slavin S, Nagler A, Naparstek E, Kapelnshnik Y, Aker M, Cividalli G, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998;91:756-63.
19. Ringdén O, Ruutu T, Remberger M, Nikoskelainen J, Volin L, Vindelöv L, et al, for the Nordic Group for Bone Marrow Transplantation. A randomized trial comparing busulphan with total body irradiation as conditioning in allogenic marrow transplant recipient with leukemia. Blood 1994;83:2723-30,
20. Remberger M, Storer B, Ringdén O, Anasetti C. Association between pretransplant thymoglobulin and reduced non-relapse mortality rate after marrow transplantation from unrelated donors. Bone Marrow Transplant 2002;29:391-7.
21. Remberger M, Svahn B-M, Hentschke P, Löfgren C, Ringdén O. Effect on cytokine release and graft-versus-host disease of different anti-T cell antibodies during conditioning for unrelated haematopoietic stem cell transplantation. Bone Marrow Transplant 1999;24:823-30.
22. Niederwieser D, Auböck J, Hajek-Rosenmayr A, Schonitzer D, Schendl D, Huber C. The role of cytokines and MHC antigens in human GVHD: analysis of T-cell specificities and endogenous cytokine levels. Bone Marrow Transplant 1989;2:84.
23. Cooke KR, Hill GR, Crawford JM, Bungard D, Brinson YS, Delmonte J Jr, Ferrara JL. Tumor necrosis factor-α production to lipopolysaccharide stimulation by donor cells predicts the severity of experimental acute graft-versus-host disease. J Clin Invest 1998;102:1882-91.
24. Hill GR, Crawford JM, Cooke KR, Brinson YS, Pan L, Ferrara JL. Total body irradiation and acute graft-versus-host disease: the role of gastrointestinal damage and inflammatory cytokines. Blood 1997;90:3204-13.
25. Imamura M, Tanaka J, Hashino S, Kobayashi H, Hirano S, Minagawa T, et al. Cytokines involved in graft-versus-host disease. Hokkaido Igaku Zasshi 1994;69:1348-53.
26. Bacigalupo A, Lamparelli T, Bruzzi P, Guidi S, Alessandrino PE, di Bartolomeo P, et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: two randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood 2001;98:2942-7.
27. Byrne JL, Stainer C, Cull G, Haynes AP, Bessel EM, Hale G, et al. The effect of the serotherapy regimen used and the marrow cell dose received on rejection, graft-versus-host disease and outcome following unrelated donor bone marrow transplantation for leukaemia. Bone Marrow Transplant 2000;25:411-7.
28. +) cell selection. Exp Hematol 2003;31:1039-43.
29. Platzbecker U, Ehninger G, Schmitz N, Bornhauser M. Reduced-intensity conditioning followed by allogeneic hematopoietic transplantation in myeloid diseases. Ann Hematol 2003;82:463-8.
30. Shlomchik WD, Couzens MS, Tang CB, McNiff J, Robert ME, Liu J, et al. Prevention of graft versus host disease by inactivation of host antigen presenting cells. Science 1999;185:412-5.
31. den Haan JM, Sherman NE, Blokland E, Huczko E, Koning F, Drijfout JW, et al. Identification of a graft versus host disease-associated human minor histocompatibility antigen. Science 1995;268:1476-80.
32. Cavet J, Dickinson AM, Norden J, Taylor PR, Jackson GH, Middleton PG. Interferon-γ and interleukin-6 gene polymorphisms associate with graft-versus-host disease in HLA-matched sibling bone marrow transplantation. Blood 2001;98: 1594-600.
33. Cullup H, Dickinson AM, Jackson GH, Taylor PR, Cavet J, Middleton PG. Donor interleukin 1 receptor antagonist genotype associated with acute graft-versus-host disease in human leucocyte antigen-matched sibling allogeneic transplants. Br J Haematol 2001;113:807-13.
34. Middleton PG, Taylor PR, Jackson G, Proctor SJ, Dickinson AM. Cytokine gene polymorphisms associating with severe acute graft-versus-host disease in HLA-identical sibling transplants. Blood 1998;92:3943-8.